

To: Driece, R.A. [(10)(2e) @minvws.nl]; [(10)(2e)] [(10)(2e) @minvws.nl]
From: [(10)(2e)]
Sent: Tue 7/14/2020 7:17:14 PM
Subject: FW: CM 3072/20 - Outcome of written procedure - Adoption PE-CONS28/20 "Regulation on clinical trials of medicinal products to treat or prevent coronavirus disease [2020/0128 (COD)]"
[cm03072.en20.docx](#)

@Roland, Ter info

[(10)(2e)] kun jij bij I&W de definitieve Kamerbrief opsporen? Dan kunnen we Angélique met een kort mailtje over de uitkomst Kamerbrief informeren.

Van: LIFE 4 Health <[(10)(2e) @consilium.europa.eu]>
Datum: dinsdag 14 jul. 2020 9:06 PM
Aan: LIFE 4 Health <[(10)(2e) @consilium.europa.eu]>
Kopie: LIFE 4 Health <[(10)(2e) @consilium.europa.eu]>
Onderwerp: CM 3072/20 - Outcome of written procedure - Adoption PE-CONS 28/20 "Regulation on clinical trials of medicinal products to treat or prevent coronavirus disease [2020/0128 (COD)]"

Dear colleagues in the Working Party on Public Health,

At yesterday's meeting I informed you that the written procedure for adoption by the Council of the "Regulation on clinical trials of medicinal products to treat or prevent coronavirus disease" would be launched and that the replies must be provided today. I can now inform you that this written procedure has been completed and that the Regulation is thus adopted. You find the mail sent today to the Mertens network below and the CM informing about the outcome attached.

Best regards,

[(10)(2e)]

Dear all,

For your information, please find attached the communication regarding the completion of the written procedure for the adoption of the Regulation of the European Parliament and of the Council on the conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or prevent coronavirus disease [2020/0128 (COD)].

Best regards,

[(10)(2e)]



Council of the European Union
General Secretariat
General and Institutional Policy

EB-07-AB-26

Rue de la Loi/Wetstraat 155 - 1040 Bruxelles/Brussel - Belgique/België

(10)(2e)

(10)(2e)

[@consilium.europa.eu](mailto:consilium.europa.eu) | www.consilium.europa.eu

Disclaimer: The views expressed are solely those of the writer and may not be regarded as stating an official position of the Council of the EU
Clause de non-responsabilité: Les avis exprimés n'engagent que leur auteur et ne peuvent être considérés comme une position officielle du Conseil de l'UE